Objective:To investigate the therapeutic effect of recombinant human brain natriuretic peptide(rhBNP)on patients with acute myocardial infarction(AMI)and heart failure(HF).Methods:This randomized controlled study enrolled 90 AMI+HF patients admitted in Zigong Fourth People's Hospital between January 2021 and Januar-y 2022.They were divided into control group(n=45,nitroglycerin therapy)and combined treatment group(n=45,lyophilized rhBNP therapy based on control group).After 3d continuous treatment,clinical therapeutic effect,serum levels of endothelin(ET)-1,nitric oxide(NO),creatine kinase isoenzyme MB(CK-MB)and cardiac tro-ponin Ⅰ(cTnⅠ)were compared between two groups.Results:Total effective rate of combined treatment group was significantly higher than that of control group(86.67%vs.68.89%,P=0.043).Compared with patients in con-trol group after treatment,those in combined treatment group had significant lower levels of cTnⅠ[(27.33±8.34)μg/L vs.(20.56±6.53)μg/L],CK-MB[(47.76±7.54)U/L vs.(25.56±5.45)U/L]and ET-1[(77.33±8.34)ng/L vs.(64.56±6.44)ng/L],and significant higher NO level[(46.76±7.54)μmol/L vs.(52.56±5.45)μmol/L](P<0.001 all).Conclusion:rhBNP has significant therapeutic effect on AMI+HF patients,it may effec-tively improve vascular endothelial function and myocardial enzyme level,which is worthy of clinical promotion.
关键词
心肌梗死/心力衰竭/冻干重组人脑利钠肽
Key words
Myocardial infarction/Heart failure/Lyophilized recombinant human brain natriuretic peptide